The U.S. liquid embolic agent market, valued at USD 66.28 million in 2024, is forecast to expand at a CAGR of 9.0% during 2025–2034, with growth accelerating through segment-wise performance that highlights the importance of product differentiation and application-specific growth. As hospitals and interventional radiology centers demand precision-targeted solutions, the market is evolving through innovations in formulation types, delivery systems, and clinical use cases.
By product type, Onyx-based agents dominate due to their established clinical outcomes and widespread FDA approval for treating AVMs. However, new-generat
Мне нравится
Комментарий
Перепост
